Actively Recruiting
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
Led by Anterogen Co., Ltd. · Updated on 2024-12-13
104
Participants Needed
4
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months
CONDITIONS
Official Title
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treated with ALLO-ASC-DFU sheet or Vehicle sheet in the phase 3 ALLO-ASC-DFU-302 clinical trial
- Able to give written informed consent before starting the study
- Willing and able to follow the study requirements
You will not qualify if you...
- Considered not suitable for the study by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Soonchunhyang University Hospital
Bucheon-si, Gyeonggi-do, South Korea, 14584
Actively Recruiting
2
Bucheon ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea, 14647
Actively Recruiting
3
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
4
Borame Medical Center
Seoul, South Korea, 07061
Actively Recruiting
Research Team
C
ChangSik Park, MD. Ph D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here